Alterity gets A$3.98m Australian R&D tax refund

Alterity Therapeutics Limited reports receiving an R&D tax refund of A$3,982,992 for the 2025 financial year, including A$43,117 in interest, under the Australian Government’s R&D tax incentive program.

Rhea-AI Filing Summary

Alterity Therapeutics Limited reports receiving an R&D tax refund of A$3,982,992 for the 2025 financial year, including A$43,117 in interest, under the Australian Government’s R&D tax incentive program.

The incentive provides a refundable tax offset of up to 43.5% for eligible R&D activities. Alterity states that this cash refund will provide important funding to continue developing its clinical programs, including its lead candidate ATH434 for Multiple System Atrophy, where it has completed Phase 2 trials and is preparing a Phase 3 pivotal study.

Insights

Biotech equity analyst

Alterity receives non-dilutive A$3.98m R&D cash refund to support trials.

Alterity Therapeutics has secured an R&D tax refund of A$3,982,992, including A$43,117 interest, via Australia’s R&D tax incentive. This refund is direct cash inflow rather than equity dilution and is tied to prior-year qualifying research activity.

The program offers a refundable tax offset of up to 43.5%, helping development-stage companies finance clinical work. Alterity notes that the funds will support ongoing clinical programs built around lead asset ATH434 in Multiple System Atrophy, where Phase 2 trials are complete and a Phase 3 pivotal trial is being prepared.

Company risk disclosures highlight typical biotech uncertainties around financing, clinical progress, regulatory approvals, safety and intellectual property. Future company filings and trial updates will clarify how long this refund supports operations and the pace of the planned Phase 3 MSA trial.

Key Figures

R&D tax refund including interest: A$3,982,992 Interest component of refund: A$43,117 Maximum refundable tax offset rate: up to 43.5%

3 metrics

R&D tax refund including interest A$3,982,992 Research and development tax refund for 2025 financial year

Interest component of refund A$43,117 Interest included within the A$3,982,992 R&D refund

Maximum refundable tax offset rate up to 43.5% Rate available under Australian Government’s R&D tax incentive

Key Terms

R&D tax incentive, refundable tax offset, Phase 3 pivotal trial, Multiple System Atrophy, +1 more

5 terms

R&D tax incentive financial

"The refund is received as part of the Australian Government’s R&D tax incentive"

A research and development (R&D) tax incentive is a government program that returns part of a company’s spending on developing new products, processes, or technologies, similar to getting a discount or rebate for innovation costs. For investors this matters because it lowers effective development costs, improves cash flow and margins, and can speed up projects—factors that affect profitability, risk and the valuation of companies pursuing new growth.

refundable tax offset financial

"provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%"

Phase 3 pivotal trial financial

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

Multiple System Atrophy medical

"developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

open label Phase 2 clinical trial medical

"Alterity has further reported positive data in its open label Phase 2 clinical trial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What R&D tax refund did Alterity Therapeutics (ATHE) receive?

Alterity Therapeutics received an R&D tax refund of A$3,982,992 for the 2025 financial year, including A$43,117 in interest. This payment comes from the Australian Government’s R&D tax incentive program and directly supports the company’s ongoing research activities.

What is the Australian R&D tax incentive mentioned by Alterity Therapeutics (ATHE)?

The Australian R&D tax incentive provides companies undertaking eligible research with a refundable tax offset of up to 43.5%. Alterity used this program to obtain a A$3,982,992 cash refund tied to its 2025 financial year research and development activities.

How will the A$3.98m R&D refund support Alterity Therapeutics’ (ATHE) programs?

Alterity states that the A$3,982,992 R&D refund will provide important funding for the continued development of its clinical programs. These programs include advancing its lead candidate ATH434 for Multiple System Atrophy, where Phase 2 studies are complete and Phase 3 preparation is underway.

What stage is Alterity Therapeutics’ (ATHE) lead drug ATH434 in for Multiple System Atrophy?

Alterity describes ATH434 as its lead asset for Multiple System Atrophy, with a completed randomized, double-blind, placebo-controlled Phase 2 trial showing clinically meaningful efficacy. The company is now preparing to initiate a Phase 3 pivotal trial in this rare disease.

What additional clinical data has Alterity Therapeutics (ATHE) reported in MSA?

Beyond the Phase 2 randomized trial, Alterity has reported positive data from an open label Phase 2 clinical trial in participants with advanced Multiple System Atrophy. These results, combined with the tax refund, support ongoing development of ATH434 and the broader pipeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 06:01 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 ATH Receives A$3.98m R&D Tax Incentive

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: July 9, 2026

2

Exhibit 99.1

Alterity Therapeutics Receives A$3.98m R&D Tax Incentive

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 9 July 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received its research and development (R&D) tax refund for the 2025 financial year, totaling A$3,982,992, including A$43,117 interest. 

The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%. The refund received will provide important funding for continued development of Alterity’s clinical programs.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorization & Additional Information

This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 11.2 KB